News about "Shanghai Biopharmaceutical companies"

Evogene's Biomica Signs Global Licensing Deal with Lishan Biotech for Microbiome-Based Cancer Therapy BMC128

Evogene's Biomica Signs Global Licensing Deal with Lishan Biotech for Microbiome-Based Cancer Therapy BMC128

Lishan Biotech secures exclusive worldwide rights to develop and commercialise BMC128, a Phase I microbiome-based immunotherapy candidate showing early promise in lung and renal cancers.

Shanghai Biopharmaceutical Companies | 07/02/2026 | By News Bureau 107


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members